aclarubicin has been researched along with Carcinoma--Bronchogenic* in 3 studies
1 trial(s) available for aclarubicin and Carcinoma--Bronchogenic
| Article | Year |
|---|---|
Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.
Topics: Aclarubicin; Adult; Aged; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carcinoma, Bronchogenic; Drug Evaluation; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Naphthacenes; Random Allocation | 1985 |
2 other study(ies) available for aclarubicin and Carcinoma--Bronchogenic
| Article | Year |
|---|---|
Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma.
Aclacinomycin A (ACLA-A) was administered to 22 patients with metastatic measurable bronchogenic squamous-cell carcinoma in a Phase II trial of the drug. Sixteen patients were fully assessable for response and toxicity. The initial dose of ACLA-A was 85 mg/m2 weekly for 4 consecutive weeks; however, due to severe myelosuppression, the weekly dose was reduced to 65 mg/m2. Fifteen patients were previously untreated. Toxicity was primarily hematological. Complete or partial responses were not observed on this treatment schedule. ACLA-A administered on this schedule lacks therapeutic efficacy in the treatment of patients with advanced bronchogenic squamous-cell carcinoma. Topics: Aclarubicin; Antibiotics, Antineoplastic; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Naphthacenes; Time Factors | 1987 |
Aclarubicin given as continuous infusion in non-small cell bronchogenic carcinoma.
Topics: Aclarubicin; Adult; Aged; Carcinoma, Bronchogenic; Female; Heart; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Naphthacenes | 1985 |